Press Releases
Press Releases
More Press Releases
View Older Stories View Newer Stories-
Stepan to Announce Third Quarter 2024 Results on October 30, 2024
-
New INTREPID Alliance Antiviral Landscape Report Highlights Urgent Need to Bolster R&D Pipeline in Support of Global Pandemic Preparedness Efforts
-
HotSpot Therapeutics to Present Preclinical Data from MALT1 CBM Signalosome Glue Program at 36th EORTC-NCI-AACR Symposium
-
AHEAD Achieves AWS Healthcare Competency Status
-
Bradford White affirms commitment to plumbing pros at ASPE Convention and Expo 2024
-
Flagship Pioneering Announces Appointment of Paul Parker as Managing Partner, Leading Capital Solutions
-
Chris Higbee Named CEO of Workplace AI – Leading Innovation in AI-Powered Workplace Solutions
-
Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader
-
Laars® Heating Systems brings innovative commercial solutions to ASPE Convention and Expo 2024
-
Primis and VideoElephant Partnership Revolutionizes Contextual Video Discovery
-
Fortune Announces the 25 Best Places to Retire Affordably
-
Athlete Career Transition (ACT) Group Ltd, Set to Launch New Digital Platform in the U.S. for Athletes Transitioning to Business Careers
-
DRIVE Roadside Revolutionizes Roadside Assistance with Free On-Demand Towing App – Available Now!
-
MADD Canada and KAG Canada Honour Alberta Victim in Road Safety Campaign
-
ScaleReady announces a G-Rex® Grant has been awarded to LIfT Biosciences
-
Alnylam Submits Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy
-
Marinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual Meeting
-
Audax Private Debt Hires John Wierzba to Lead Wealth Effort
-
Evergold Awaits New Drill Assays from DEM Porphyry “Halo”, Identifies Likely Location of Intrusive Centre
-
Veritone Expands iDEMS Data Integrations to Enhance Public Safety and Law Enforcement Efficiency
-
Amprion Announces Initial Close of a $15M Financing to Commercialize Groundbreaking Neurologic Diagnostics
-
WELL Health Announces Positive Findings from AI Scribe Evaluation Study Conducted by OntarioMD
-
Vizgen and Ultivue Merge to Enable Deeper Insights into Disease Mechanisms and Drive Innovation in Spatial Multi-Omics
-
Sonendo Executes Asset Purchase Agreement to Acquire Biolase Assets
-
LITHION BECOMES HYUNDAI'S OFFICIAL PARTNER FOR THE COLLECTION AND RECYCLING OF ELECTRIC VEHICLE BATTERIES IN CANADA
-
MyGuava Partners with QPR to Unveil Exclusive Fan Payment Cards and Exciting Rewards
-
C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit
-
Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ENA 2024
-
Case Status Announces $19.7M Series B Investment to Use A.I. to Transform Legal Client Engagement
-
Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4
-
D-Wave Brings Quantum Optimization to 2024 INFORMS Annual Meeting
-
QuidelOrtho Announces New R&D Executive Leader
-
Survey Reveals that Half of U.S. Enterprises Have Immature External Attack Surface Management Programs Despite 90% Indicating Increases in Impactful Incidents
-
BMO Launches PaySmart™ Credit Card Installment Plan Feature in the U.S.
-
New Prospective, Multicenter Study Presented at SMR Demonstrates Castle Biosciences’ DecisionDx®-Melanoma Test Provides Significant Risk Prediction for Patients with Cutaneous Melanoma, Adding Valu
-
Pillar Security’s State of Attacks on GenAI: 90% of Successful Attacks Seen in the Wild Resulted in Leaked Sensitive Data
-
InspiroGene by McKesson Unveils First-of-its-Kind Report on State of the Cell and Gene Therapy Landscape, Revealing Unparalleled Optimism Amidst Complex Challenges
-
insitro and Lilly Enter Strategic Agreements to Advance Novel Treatments for Metabolic Diseases
-
Transposon to Present Results from Phase 2 Study of TPN-101 for the Treatment of C9orf72-Related ALS/FTD at the 2024 Annual NEALS Meeting
-
clock.bio Raises $5.3M Seed Funding and Decodes Genetic Atlas of Human Rejuvenation Factors
-
Kinterra Capital Affiliate Completes Acquisition of Nevada Copper’s Open Pit and Underground Copper Projects
-
Zai Lab to Present Data from Phase 1 Trial of ZL-1310, Its Investigational Antibody-Drug Conjugate (ADC) for DLL3+ Solid Tumors, at EORTC-NCI-AACR Symposium (ENA) 2024
-
Nurix Therapeutics Announces Presentations at ACR Convergence 2024, the Annual Meeting of the American College of Rheumatology
-
Net3.org Launches Beacon Network for Privacy-Enhanced Communications
-
SemiCab Wins Major New Contract with $10 Billion Indian Consumer Packaged Goods Company for New Pilot in India
-
FDA Grants Orphan Drug Designation to Can-Fite’s Namodenoson for Pancreatic Cancer
-
Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
-
OTC Markets Group Welcomes SulNOx Group Plc to OTCQX
-
C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit
-
Stella-Jones Will Hold a Conference Call to Discuss its Third Quarter Results
